De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

نویسندگان

  • G Curigliano
  • H J Burstein
  • E P Winer
  • M Gnant
  • P Dubsky
  • S Loibl
  • M Colleoni
  • M M Regan
  • M Piccart-Gebhart
  • H-J Senn
  • B Thürlimann
  • F André
  • J Baselga
  • J Bergh
  • H Bonnefoi
  • S Y Brucker
  • F Cardoso
  • L Carey
  • E Ciruelos
  • J Cuzick
  • C Denkert
  • A Di Leo
  • B Ejlertsen
  • P Francis
  • V Galimberti
  • J Garber
  • B Gulluoglu
  • P Goodwin
  • N Harbeck
  • D F Hayes
  • C-S Huang
  • J Huober
  • K Hussein
  • J Jassem
  • Z Jiang
  • P Karlsson
  • M Morrow
  • R Orecchia
  • K C Osborne
  • O Pagani
  • A H Partridge
  • K Pritchard
  • J Ro
  • E J T Rutgers
  • F Sedlmayer
  • V Semiglazov
  • Z Shao
  • I Smith
  • M Toi
  • A Tutt
  • G Viale
  • T Watanabe
  • T J Whelan
  • B Xu
چکیده

The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer. Treatments were assessed in light of their intensity, duration and side-effects, seeking where appropriate to escalate or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology. The Panel favored several interventions that may reduce surgical morbidity, including acceptance of 2 mm margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following neoadjuvant treatment of many patients, and the preference for neoadjuvant therapy in HER2 positive and triple-negative, stage II and III breast cancer. The Panel favored escalating radiation therapy with regional nodal irradiation in high-risk patients, while encouraging omission of boost in low-risk patients. The Panel endorsed gene expression signatures that permit avoidance of chemotherapy in many patients with ER positive breast cancer. For women with higher risk tumors, the Panel escalated recommendations for adjuvant endocrine treatment to include ovarian suppression in premenopausal women, and extended therapy for postmenopausal women. However, low-risk patients can avoid these treatments. Finally, the Panel recommended bisphosphonate use in postmenopausal women to prevent breast cancer recurrence. The Panel recognized that recommendations are not intended for all patients, but rather to address the clinical needs of the majority of common presentations. Individualization of adjuvant therapy means adjusting to the tumor characteristics, patient comorbidities and preferences, and managing constraints of treatment cost and access that may affect care in both the developed and developing world.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017) Erstbehandlung von Patientinnen mit primärem Mammakarzinom: Evidenz, Kontroversen, Konsens

The St. Gallen International Consensus Conference on the treatment of patients with primary breast cancer has been held regularly (every second year in the last six years) for more than 30 years. This year, the findings of the International St. Gallen Consensus Panel and their implications for clinical practice were again discussed by a German working group of leading breast cancer specialists....

متن کامل

St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment.

For the second time, the St. Gallen Consensus Conference on early breast cancer treatment standards took place in Vienna, Austria, where it will remain for the foreseeable future (next date: March 20-23, 2019). With the probably most prominent line-up of global breast cancer experts and more than 3,000 participants from over 100 countries, the 2017 St. Gallen/Vienna conference again was a huge ...

متن کامل

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer

Citation Coates, A. S., E. P. Winer, A. Goldhirsch, R. D. Gelber, M. Gnant, M. Piccart-Gebhart, B. Thürlimann, and H.-J. Senn. 2015. “Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.” Annals of Oncology 26 (8): 1533-1546. doi:10.1093/annonc/mdv221. http://dx.doi.org/10.1093/annonc/md...

متن کامل

Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus Opinions of German Specialists to the 14th St. Gallen International Breast Cancer

For the first time, this yearʼs St. Gallen International Consensus Conference on the treatment of patients with primary breast cancer, which takes place every two years, was held not in St. Gallen (Switzerland) but – for logistical reasons – in Vienna (Austria) under its usual name. The 2015 St. Gallen International Consensus Conference was the 14th of its kind. As the international panel of th...

متن کامل

14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.

The key topics of this year's 14th St. Gallen Consensus Conference on the diagnosis and therapy of primary breast cancer were again questions about breast surgery and axillary surgery, radio-oncology and systemic therapy options in consideration of tumor biology, and the clinical application of multigene assays. This year, the consensus conference took place in Vienna. From a German perspective...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Annals of oncology : official journal of the European Society for Medical Oncology

دوره 28 8  شماره 

صفحات  -

تاریخ انتشار 2017